Catalyst
Slingshot members are tracking this event:
Alnylam (ALNY) Expects to Initiate Phase 3 Trial in Late 2017 Study Evaluating Givosiran (ALN-AS1) for the Treatment of Acute Hepatic Porphyrias
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2017
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1039464
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Aln-as1, Phase 1 Study Results, Initiation, Phase 3 Trial, Givosiran
